NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NHLBI E-156-2016-0-AU-03 ADENO-ASSOCIATED VIRUS POLYNUCLEOTIDES, POLYPEPTIDES AND VIRIONS AU National Stage 2017261249 Issued
NHLBI E-186-2014-1-US-08 METHOD OF TREATING GRAFT VERSUS HOST DISEASE WITH AN INTERLEUKIN-2 MUTEIN US DIV 16/175,709 10654905 Issued PDF
NHGRI E-034-2019-0-PCT-02 Targeted Integration Into The Albumin (Alb) Locus As A Treatment For Hereditary Methylmalonic Acidemia (MMA) Caused By Methylmalonyl-coA Mutase (MUT) Deficiency PCT PCT PCT/US2018/058307 Expired
NCATS E-101-2017-0-PCT-02 SUBSTITUTED QUINOLINE ANALOGS AS ALDEHYDE DEHYDROGENASE 1A1 (ALDH1A1) INHIBITORS PCT PCT PCT/US2018/058257 Expired
NLM E-107-2010-2-US-24 SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET -FAMILY PROTEINS US CON 16/175,353 Abandoned
NHGRI E-034-2019-0-CN-13 NON-DISRUPTIVE GENE THERAPY FOR THE TREATMENT OF MMA CN National Stage 201880098490.X Pending
NHGRI E-034-2019-0-EP-03 NON-DISRUPTIVE GENE THERAPY FOR THE TREATMENT OF MMA EP National Stage 18929532.2 Pending
NHGRI E-034-2019-0-IN-14 NON-DISRUPTIVE GENE THERAPY FOR THE TREATMENT OF MMA IN National Stage 202117007847 Pending
NHGRI E-034-2019-0-JP-09 NON-DISRUPTIVE GENE THERAPY FOR THE TREATMENT OF MMA JP National Stage 2021-531445 Pending
NHGRI E-034-2019-0-MX-05 NON-DISRUPTIVE GENE THERAPY FOR THE TREATMENT OF MMA MX National Stage MX/a/2021/001062 Pending
NHGRI E-034-2019-0-CA-11 NON-DISRUPTIVE GENE THERAPY FOR THE TREATMENT OF MMA CA National Stage 3109114 Pending
NHGRI E-034-2019-0-BR-08 Targeted Integration Into The Albumin (Alb) Locus As A Treatment For Hereditary Methylmalonic Acidemia (MMA) Caused By Methylmalonyl-coA Mutase (MUT) Deficiency BR National Stage BR112021002332-1 Pending
NHGRI E-034-2019-0-AU-04 NON-DISRUPTIVE GENE THERAPY FOR THE TREATMENT OF MMA AU National Stage 2018436152 Pending
NHGRI E-034-2019-0-IL-06 Targeted Integration Into The Albumin (Alb) Locus As A Treatment For Hereditary Methylmalonic Acidemia (MMA) Caused By Methylmalonyl-coA Mutase (MUT) Deficiency IL National Stage 1984-06-28 Pending
NHGRI E-034-2019-0-KR-15 Targeted Integration Into The Albumin (Alb) Locus As A Treatment For Hereditary Methylmalonic Acidemia (MMA) Caused By Methylmalonyl-coA Mutase (MUT) Deficiency KR National Stage 10-2021-7007207 Pending
NHGRI E-034-2019-0-RU-12 NON-DISRUPTIVE GENE THERAPY FOR THE TREATMENT OF MMA RU National Stage 2021105822 Pending
NHGRI E-034-2019-0-SA-10 Targeted Integration Into The Albumin (Alb) Locus As A Treatment For Hereditary Methylmalonic Acidemia (MMA) Caused By Methylmalonyl-coA Mutase (MUT) Deficiency SA National Stage 521421222 Pending
NCI E-269-2010-0-US-13 ANTI-SSX-2 T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE US CON 16/173,701 10864252 Issued PDF
NIAID E-139-2006-0-US-65 DEVELOPMENT OF DENGUE VIRUS VACCINE COMPONENTS US DIV 16/173,217 10724007 Issued PDF
NCI E-190-2014-0-JP-13 VIRUS-LIKE PARTICLE CONJUGATES FOR DIAGNOSIS AND TREATMENT OF
TUMORS 		JP DIV 2018-202650 Issued
NCI E-229-2017-0-PCT-02 TREATING OR PREVENTING ADVERSE LIVER CONDITIONS PCT PCT PCT/US2018/057946 Expired
NIDCR E-184-2017-0-PCT-02 JACKETED CATHETER PROBES AND METHODS OF USE FOR INFUSION PCT PCT PCT/US2018/057744 Expired
NLM E-107-2010-2-US-23 SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET -FAMILY PROTEINS US CON 16/172,369 Abandoned
NIDCR E-184-2017-0-EP-03 JACKETED CATHETER PROBES AND METHODS OF USE FOR INFUSION EP National Stage 18800450.1 Abandoned
NCATS E-116-2016-0-EP-06 CRYSTAL FORMS AND METHODS OF SYNTHESIS OF (2R, 6R)-HYDROXYNORKETAMINE AND (2S, 6S)-HYDROXYNORKETAMINE EP National Stage 17716350.8 Pending
NHGRI E-044-2013-1-US-16 Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human Lamin A (LMNA) US National Stage 16/096,524 Pending
NCI E-153-2016-0-US-06 ANTI-KK-LC-1 T CELL RECEPTORS US National Stage 16/096,118 11352410 Issued PDF
NLM E-107-2010-2-US-22 SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET -FAMILY PROTEINS US CON 16/169,801 10465234 Issued PDF
NINDS E-146-2016-1-FR-06 Selective D3 Dopamine Receptor Agonists and Methods of Their Use FR EP 17733098.2 Issued
NINDS E-146-2016-1-DE-04 Selective D3 Dopamine Receptor Agonists and Methods of Their Use DE EP 17733098.2 Issued
NINDS E-146-2016-1-EP-02 Selective D3 Dopamine Receptor Agonists and Methods of Their Use EP National Stage 17733098.2 Issued
NINDS E-146-2016-1-IE-08 Selective D3 Dopamine Receptor Agonists and Methods of Their Use IE EP 17733098.2 Issued
NINDS E-146-2016-1-BE-07 Selective D3 Dopamine Receptor Agonists and Methods of Their Use BE EP 17733098.2 Issued
NINDS E-146-2016-1-GB-05 ESelective D3 Dopamine Receptor Agonists and Methods of Their Use GB EP 17733098.2 Issued
NINDS E-146-2016-1-CH-09 Selective D3 Dopamine Receptor Agonists and Methods of Their Use CH EP 17733098.2 Issued
NCI E-008-2018-0-GB-10 OPTICAL CONFIGURATION METHODS FOR SPECTRAL SCATTER FLOW CYTOMETRY GB EP 18808559.1 Issued
NCI E-008-2018-0-NL-11 OPTICAL CONFIGURATION METHODS FOR SPECTRAL SCATTER FLOW CYTOMETRY NL EP 18808559.1 Issued
NCI E-008-2018-0-DE-08 OPTICAL CONFIGURATION METHODS FOR SPECTRAL SCATTER FLOW CYTOMETRY DE EP 18808559.1 Issued
NCI E-008-2018-0-FR-09 OPTICAL CONFIGURATION METHODS FOR SPECTRAL SCATTER FLOW CYTOMETRY FR EP 18808559.1 Issued
NCI E-008-2018-0-EP-04 OPTICAL CONFIGURATION METHODS FOR SPECTRAL SCATTER FLOW CYTOMETRY EP National Stage 18808559.1 Issued
NCI E-008-2018-0-KR-06 OPTICAL CONFIGURATION METHODS FOR SPECTRAL SCATTER FLOW CYTOMETRY KR National Stage 10-2020-7011517 Issued
NCI E-008-2018-0-JP-05 OPTICAL CONFIGURATION METHODS FOR SPECTRAL SCATTER FLOW CYTOMETRY JP National Stage 2020-522670 Issued
NCI E-008-2018-0-PCT-02 OPTICAL CONFIGURATION METHODS FOR SPECTRAL SCATTER FLOW CYTOMETRY PCT PCT PCT/US2018/057128 Expired
NCI E-008-2018-0-CN-03 OPTICAL CONFIGURATION METHODS FOR SPECTRAL SCATTER FLOW CYTOMETRY CN National Stage 201880069066.2 Pending
NIDDK E-138-2017-0-IL-08 COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS IL National Stage 262487 Issued
NCI E-131-2016-0-US-07 EVALUATON OF MANTLE CELL LYMPHOMA AND METHODS RELATED THERETO US National Stage 16/094,965 11725248 Issued PDF
NCI E-153-2016-0-IE-15 ANTI-KK-LC-1 T CELL RECEPTORS IE EP 17733120.4 Issued
NCI E-153-2016-0-IT-16 ANTI-KK-LC-1 T CELL RECEPTORS IT EP 17733120.4 Issued
NCI E-153-2016-0-NL-17 ANTI-KK-LC-1 T CELL RECEPTORS NL EP 17733120.4 Issued
NCI E-153-2016-0-CH-08 ANTI-KK-LC-1 T CELL RECEPTORS CH EP 17733120.4 Issued